oa Immunocompromised Patient with Bilateral Pulmonary Infiltrates (Docetaxel Induced Hypersensitivity Interstitial Pneumonitis)

References

1. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005; 65:17, : 25, 13–31.
   [Google Scholar]
2. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999; 36:2:99–114.
   [Google Scholar]
3. Taxotere.com for Healthcare Professionals: Efficacy and Safety. Sanofi-aventis U.S. LLC. http://www.taxotere.com/professional/about/efficacy_safety.do (6 Nov 2008).
4. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. London: Churchill Livingstone 2003;:694–698.
   [Google Scholar]
5. Kunitah H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T. Phase II trial of docetaxel in previously untreated advanced non smallcell lung cancer: A Japanese cooperative study. J Clin Oncol. 1996; 14::1649–1665.
   [Google Scholar]
6. Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer. 2001; 85::1247–1250.
   [Google Scholar]
7. Rowinsky EK, Donehower RC. The clinical pharmacology ofpaclitaxel (TAXOL(r)). Semin Oncol. 1993; 20:Suppl 3:16.
   [Google Scholar]
8. Horwitz SB. Mechanism of action oftaxol. Trends Pharmacol Sci. 1992; 13::134.
   [Google Scholar]
9. Thomas AL, Cox G, Sharma RA. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: Report of a phase l/lI dose-escalating study. Eur J Cancer. 2000; 36::2329.
   [Google Scholar]
10. Dunsford ML, Mead GM, Bateman AC. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol. 1999; 10::943.
    [Google Scholar]
11. Yu TK, Whitman GJ, Thames HD. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004; 96::1676.
    [Google Scholar]
12. Taghian AG, Assaad SI, Niemierko A. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst. 2001; 93::1806.
    [Google Scholar]
13. Beal K, Hudis C, Norton L. Radiation pneumonitis in breast cancer patients treated with taxanes: Does sequential radiation therapy lower the risk? Breast J. 2005; 11::317.
    [Google Scholar]
14. Hamourl M, Mittal TK, Bell AD. Banner NR of Heart Lung Transplant. 2006 Feb; 25:2:241–244, . Epub 2995 Dec 20.
    [Google Scholar]
15. Holy PY, Luna MA, Mackay B, Bedrossian CWM. Bleomycin induced hypersensitivity pneumonitis (1978). AM Int Med. 1978; 88::47–49.
    [Google Scholar]
16. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease. Parti: Cytotoxic drugs. Am Rev Respir Dis. 1986; 133::321–321.
    [Google Scholar]
17. Guillon JM, Joly P, Austrian B, Denis MA. Minocycline-induced cellmediated hypersensitivity pneumonitis. Am Int Med. 1992; 117::467–481.
    [Google Scholar]